Genmab

	15/10 17:07 af Vitus	Ikke lige dagen man er så glad for at have Genmab (eller foruden sags skyld BAVA)..
	15/10 17:07 af AaBforever	Jeps..da skulle man have tømt alle sparebøsser, belånt huset til op over skorstenen og købt aktier for det hele.
	15/10 17:07 af Klarussen	Ville have været fantastisk at samle op i 1090, så heldig var jeg ikke. Og de 2066 den tangerede 23/9 var jeg ikke hurtig nok på aftrækkeren til, desværre. Der skulle man vist have været hurtigere end Lucky Luke.
	15/10 17:03 af gdn55	Eller den 15.03, da den var nede omkring 1090
	15/10 16:50 af Klarussen	Ja, det var tider
	15/10 16:49 af gdn55	Jeg køber kun. Har gjort det siden kurs 35,60 i 2011.
	15/10 16:48 af Klarussen	Jo, men med den her fart kan det heller ikke vare længe ;-)
	15/10 16:45 af AaBforever	Der er da heldigvis et godt stykke ned til 2050...var det ikke der du ville ind?
	15/10 16:43 af Klarussen	Fint at kursen kommer ned i et mere realistisk leje. Afventer dog yderligere fald inden genkøb.
	15/10 16:36 af AaBforever	Den får godt nok tæsk i dag.
	15/10 15:55 af AaBforever	Det er altid rart at se frem til noget positivt på en dag som i dag:-)
	15/10 15:16 af Solsen	Spændende at se frem til ;-)
	15/10 15:15 af Solsen	Media Release Copenhagen, Denmark, October 15, 2020 Genmab will host Capital Markets Day November 13, 2020 Highlights to be covered will include an overview of our pipeline with focus on epcoritamab, tisotumab vedotin and DuoBody®-PD-L1x4-1BB, our DuoBody® technology platform, and insights into our growing capabilities across Genmab
	15/10 13:59 af AaBforever	Kursmålet på Genmab-aktien er torsdag blevet hævet til 2500 kr. fra tidligere 1750 kr. af finanshuset Kempen & Co. Anbefalingen lyder fortsat på køb./ritzau/FINANS
	15/10 12:12 af E L	any thoughts/speculations on that new Talquetamab/Teclistamab trial? I guess we have to see this in the context of the existing trial combining them with Dara? But that started only in February, I doubt they have seen any real data on that yet? (link)
	15/10 10:40 af E L	i don't think anyone has seen the data really, i wouldn't worry about that
	15/10 10:31 af GeorgeBest	A bit dissapointing that there haven‘t been any comments from oncologists so far
	15/10 10:30 af GeorgeBest	I have seen it, thank you.
	15/10 10:22 af E L	i posted a picture of the abstract on twitter by the way, you can check there (until they take me down ;-)
	15/10 10:21 af E L	exactly because liver tox was an issue before, I was not disappointed with this. Surely we'll hear a bit more about this in november
	15/10 10:21 af E L	6 out of 61, treatment with corticosteroid seems to help, maximum tolerated dose was not reached
	15/10 10:19 af E L	yes, offcourse
	15/10 10:17 af GeorgeBest	Liver tox have in the past been a problem and hindernis for 4-1BB drugs, and therefore this has to be monitored closely they conclude
	15/10 10:14 af GeorgeBest	I have not seen the note myself, but 6 patients had dose limiting tox incl elevated liver enzymes they write

	15/10 10:12 af GeorgeBest	Yes
	15/10 10:09 af E L	did Nordea base their doubts on that abstract?
	15/10 09:54 af GeorgeBest	Thank you, there were some doubts from Nordea, but very impressive on efficiacy on those heavily pretreated patients they apparently concluded
	15/10 09:49 af E L	so in summary they concluded manageable safety profile
	15/10 09:49 af E L	treatment related grade-3 transaminase elevatoins decreased upon corticosteroid administration, no treatment related bilirubin increases or grade-4 transaminase elevatoins occured
	15/10 09:47 af E L	There was transaminise elevation , 24.6% all grades, 9.8% grade 3-4
	15/10 09:46 af E L	"sorry can't tell you; it is under embargo" ;-)
	15/10 09:37 af GeorgeBest	Any opinion about the liver tox in GEN1046?
	15/10 09:30 af E L	New trial: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (link)
	15/10 09:20 af E L	just checked we have to wait till oct27 for Novartis Q3 to get the first glimpse
	15/10 09:17 af Solsen	Ja Ocrevus er vild. Også spændende hvad Novartis kan gøre ved Roche.
	15/10 09:16 af Solsen	Mange patienter kun behandlet kort tid og flere med meget små doser.
	15/10 09:16 af Solsen	Det var spændende data på GEN1046, men vi må vente med at se hvor gode de egentlig er. Mange ots kun behandlet e
	15/10 09:14 af Bulder	;-)
	15/10 09:08 af E L	and Society for Immunotherapy of Cancer @sitcancer suddenly started following me on twitter; they are on to me ! :-D
	15/10 09:06 af E L	exactly lol. the links also don't work anymore
	15/10 09:03 af Sukkeralf	I was also wondering about that because it should have been at late last night at kl 23 and only titles
	15/10 08:59 af E L	It appears we had a real scoop here yesterday with those SITC abstracts... I was already surprised they were hours early, and even more surprised we could see the content... it seems to have been a mistake lol
	15/10 08:53 af Helge Larsen/PI-redaktør	Tak Sukker. Det er imponerende.
	15/10 08:42 af Sukkeralf	Ocrevus begynder at ligne et 5 milliard dollar drug - bare GSK i sin tid havde sat mere fart over feltet :-(
	15/10 08:41 af Sukkeralf	(link)
	15/10 08:40 af Sukkeralf	Lad os håbe Novartis begynder at tage markedsandele med Kesimpta, for Ocrevus kører bare derudaf: Roche Q3 sales for Ocrevus: CHF 1.2 billion, up 37%
	15/10 08:20 af Helge Larsen/PI-redaktør	Genmab @Genmab We’re excited to share updates from Genmab’s pipeline at the virtual #SITC2020, including first-in-human data on a bispecific antibody in joint development with (link)
	15/10 07:36 af transalp	Go morgen.. :)
	15/10 02:27 af SEACOP	(link)
	15/10 02:27 af SEACOP	Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting.